Results 231 to 240 of about 103,755 (281)
Some of the next articles are maybe not open access.
Treatment of Acinetobacter spp. infections
Expert Opinion on Pharmacotherapy, 2003Acinetobacter spp. are predominantly nosocomial pathogens of growing importance. One of their important features is antimicrobial resistance that includes beta-lactams, aminoglycosides and quinolones. Imipenem, considered the most effective drug against Acinetobacter spp., is not universally active against clinical isolates and therapeutic options are ...
Anna Sara Levin
openaire +4 more sources
Acinetobacter Baumannii Nosocomial Infections
Polish Journal of Surgery, 2013Nosocomial infections caused by strains Acinetobacter baumannii strands are a growing clinical problem. The occurrence of multidrug-resistant strands is observed and that limits the ways of therapy considerably. The aim of the study was to determine the rate of infection and susceptibility spectrum of the species Acinetobacter baumannii isolated from ...
Karol, Sieniawski +4 more
openaire +2 more sources
Community-acquired Acinetobacter infections
European Journal of Clinical Microbiology & Infectious Diseases, 2007Acinetobacter infections have been attracting increasing attention during recent years because they have become common in hospitalized patients, especially in the intensive care unit (ICU) setting. However, the available literature suggests that the pathogen has another fearful potential; it can cause community-acquired infections.
M E, Falagas +3 more
openaire +2 more sources
Acinetobacter Infections in Neonates
Current Infectious Disease Reports, 2018MDR-Gram-negative bacteria are a great concern in the neonatal population, with a worldwide rise in the reported incidence and with very limited therapeutic options. Acinetobacter baumannii is responsible for many infections in neonates and outbreaks in neonatal intensive care unit (NICU); also, outbreaks caused by other Acinetobacter species have been
Raffaele Zarrilli +3 more
openaire +4 more sources